Penel N, Watelle F, Vanhuyse M, Adenis A
Centre Oscar-Lambret, Département de cancérologie générale, 3, rue F.-Combemale, 59020 Lille, France.
Bull Cancer. 2010 Jun;97(6):687-91. doi: 10.1684/bdc.2010.1124.
We describe herein the current concepts tested in clinical trials dedicated to patients with metastatic soft tissue sarcomas: identify predictive factors under anthracyclin-based regimens, identify patients beneficing from polychemotherapy, benefit of maintenance treatment, use of non-progression rate rather than response rate for selecting new drugs, histology-tailored or biological target-tailored second-line treatment.
确定基于蒽环类方案的预测因素,确定从多药化疗中获益的患者,维持治疗的益处,使用无进展率而非缓解率来选择新药,组织学或生物靶点定制的二线治疗。